No correlations between the development of specific IgA and IgM antibodies against anti-TNF blocking agents, disease activity and adverse side reactions in patients with rheumatoid arthritis

Open Rheumatology Journal

Volumn 7, Issue 1, 2013, Pages 75-80

  Benucci, Maurizio ^a   Saviola, Gianantonio ^b   Meacci, Francesca ^a   Manfredi, Mariangela ^a   Infantino, Maria ^a   Campi, Paolo ^a   Severino, Maurizio ^a   Iorno, Miriam ^a   Sarzi Puttini, Piercarlo ^c   Atzeni, Fabiola ^c  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b IRCCS Salvatore Maugeri   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Adverse events; Antibodies; Disease activity; Rheumatoid arthritis; TNF blockers

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; METHOTREXATE;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG SAFETY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84885628106     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901307010075     Document Type: Article

References (21)

1. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-90.
2. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
3. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
4. Pichler WJ, Campi P. Adverse side effects to biological agents. In Pichler WJ editor. Drug Hypersensitivity. Basel: Karger; 2007: pp. 160-74.
5. Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-61.
6. Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol 2009; 27(2): 333-6.
7. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up. JAMA 2011; 305: 1460-8.
8. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010; 69: 817-21.
9. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284-8.
10. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
11. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010; 12: 217.
12. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-45.
13. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
14. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66: 253-6.
15. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21: 211-5.
16. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011; 372: 196-203.
17. Wadhwa M, Thorpe R. Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis 2010; 2: 1073-84.
18. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol 2012; 24: 306-11.
19. van der Maas A, van den Bemt BJ, Wolbink GJ, et al. Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskelet Disord 2012; 13: 184.
20. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164-72.
21. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72(2): 165-78.